Ultragenyx
Tracked across 3 events · 44 articles · First seen Feb 05, 2026 · Last active May 27, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Ultragenyx announced that the United States — Food and Drug Administration accepted its resubmitted Biologics License Application for UX111, bringing it closer to potential approval for Sanfilippo syndrome Type A.
Apr 02, 2026 · 6 articles
Business
Impact: Ultragenyx is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its Phase III Orbit and Cosmic Studies for setrusumab, leading to a significant drop in its stock price.
Feb 05, 2026 · 31 articles
Business
Impact: Ultragenyx is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Feb 26, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Ultragenyx live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard